Biogen Inc.

BOVESPA:BIIB34 Stock Report

Market Cap: R$137.2b

Biogen Past Earnings Performance

Past criteria checks 4/6

Biogen's earnings have been declining at an average annual rate of -30.4%, while the Biotechs industry saw earnings growing at 13.3% annually. Revenues have been declining at an average rate of 9.8% per year. Biogen's return on equity is 9.9%, and it has net margins of 16.8%.

Key information

-30.4%

Earnings growth rate

-24.3%

EPS growth rate

Biotechs Industry Growth14.8%
Revenue growth rate-9.8%
Return on equity9.9%
Net Margin16.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Biogen makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BOVESPA:BIIB34 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 249,6081,6152,3162,067
30 Jun 249,6721,1592,4892,212
31 Mar 249,6631,1672,4762,333
31 Dec 239,8361,1612,5022,458
30 Sep 239,9931,4622,5322,490
30 Jun 239,9722,6652,3432,303
31 Mar 2310,1053,1312,3792,248
31 Dec 2210,1733,0472,4092,229
30 Sep 2210,3632,8652,5702,325
30 Jun 2210,6342,0592,6612,478
31 Mar 2210,8201,4502,7262,535
31 Dec 2110,9821,5562,6802,497
30 Sep 2111,1011,5462,7003,522
30 Jun 2111,6981,9182,6193,960
31 Mar 2112,6043,0122,5364,023
31 Dec 2013,4454,0012,5163,985
30 Sep 2014,2635,0822,3702,949
30 Jun 2014,4875,9272,3512,348
31 Mar 2014,4225,8792,3652,178
31 Dec 1914,3785,8892,3592,273
30 Sep 1914,2335,3962,2852,193
30 Jun 1914,0725,2942,2292,160
31 Mar 1913,8124,6672,1762,664
31 Dec 1813,4534,4312,1092,597
30 Sep 1813,2343,1872,0702,573
30 Jun 1812,8722,9682,0072,512
31 Mar 1812,5942,9641,9212,327
31 Dec 1712,2742,5391,9362,254
30 Sep 1711,8393,4861,8592,200
30 Jun 1711,7173,2931,8872,283
31 Mar 1711,5333,4801,9491,959
31 Dec 1611,4493,7031,9501,973
30 Sep 1611,4163,8852,0351,981
30 Jun 1611,2383,8182,0511,972
31 Mar 1610,9363,6952,0501,990
31 Dec 1510,7643,5472,1132,013
30 Sep 1510,5653,5992,1041,971
30 Jun 1510,2993,4902,1961,869
31 Mar 1510,1283,2772,2811,825
31 Dec 149,7032,9352,2321,893
30 Sep 149,0282,5092,1541,816
30 Jun 148,3452,1391,9901,808
31 Mar 147,6471,9161,8441,689
31 Dec 136,9321,8621,7121,444

Quality Earnings: BIIB34 has high quality earnings.

Growing Profit Margin: BIIB34's current net profit margins (16.8%) are higher than last year (14.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BIIB34's earnings have declined by 30.4% per year over the past 5 years.

Accelerating Growth: BIIB34's earnings growth over the past year (10.5%) exceeds its 5-year average (-30.4% per year).

Earnings vs Industry: BIIB34 earnings growth over the past year (10.5%) exceeded the Biotechs industry 7.1%.

Return on Equity

High ROE: BIIB34's Return on Equity (9.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 07:47
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biogen Inc. is covered by 74 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Steven ChesneyAtlantic Equities LLP
Brian SkorneyBaird